Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27933237 | 0.85 | HPGD (0.39) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30496171 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3791629 | 0.80 | HPGD (0.51) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL497229 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10527716 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25198363 | 0.80 | ALDH1A1 (0.53) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15436874 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14510730 | 0.80 | HPGD (0.41) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30496159 | 0.80 | ALDH1A1 (0.53) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7213726 | 0.77 | HPGD (0.49) | HPGDCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331673-A1 | COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE | CRESCENTA BIOSCIENCES (US) | 2023-10-19 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| WO-2016202898-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| CN-103848811-B | Uracil derivant, its preparation method and application thereof | 齐鲁制药有限公司 | 2016-12-21 | — | — | CN | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331673-A1 | COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE | FABP4, FABP1, FABP3 | HPGD 4289/4885CYP1A2 2551/4885CYP2D6 1424/4885 |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | HPGD 87/4885CYP1A2 1878/4885CYP2D6 3368/4885 |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | HPGD 842/4885CYP1A2 952/4885CYP2D6 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.